ATE298753T1 - Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung der sexuellen dysfunktion - Google Patents

Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung der sexuellen dysfunktion

Info

Publication number: ATE298753T1
Authority: AT; Austria
Prior art keywords: treatment; sexual dysfunction; cgmp pde5; pde5 inhibitors; pyrazolopyrimidinone cgmp
Prior art date: 1998-10-23

Application number

AT99308158T

Other languages

English (en)

Inventor

Mark Edward Bunnage

Stephen Derek Albert Street

John Paul Mathias

Anthony Wood

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-23

Filing date

1999-10-15

Publication date

2005-07-15

1999-10-15 Application filed by Pfizer filed Critical Pfizer

2005-07-15 Application granted granted Critical

2005-07-15 Publication of ATE298753T1 publication Critical patent/ATE298753T1/de

Links

229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title 1
201000001880 Sexual dysfunction Diseases 0.000 title 1
239000002590 phosphodiesterase V inhibitor Substances 0.000 title 1
DOTPSQVYOBAWPQ-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-3-one Chemical compound N1=CN=C2C(=O)N=NC2=C1 DOTPSQVYOBAWPQ-UHFFFAOYSA-N 0.000 title 1
231100000872 sexual dysfunction Toxicity 0.000 title 1
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract 2
101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 abstract 1
101150098694 PDE5A gene Proteins 0.000 abstract 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
238000009109 curative therapy Methods 0.000 abstract 1
ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT99308158T 1998-10-23 1999-10-15 Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung der sexuellen dysfunktion ATE298753T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9823103.8A GB9823103D0 (en)	1998-10-23	1998-10-23	Pharmaceutically active compounds

Publications (1)

Publication Number	Publication Date
ATE298753T1 true ATE298753T1 (de)	2005-07-15

Family

ID=10841069

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99308158T ATE298753T1 (de)	1998-10-23	1999-10-15	Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung der sexuellen dysfunktion

Country Status (9)

Country	Link
US (1)	US6407114B1 (de)
EP (1)	EP0995751B1 (de)
JP (1)	JP3670908B2 (de)
AT (1)	ATE298753T1 (de)
BR (1)	BR9905109A (de)
CA (1)	CA2287562A1 (de)
DE (1)	DE69925970T2 (de)
ES (1)	ES2243037T3 (de)
GB (1)	GB9823103D0 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9423910D0 (en) *	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
SE9902270D0 (sv) *	1999-06-16	1999-06-16	Astra Ab	Pharmaceutically active compounds
US7235625B2 (en)	1999-06-29	2007-06-26	Palatin Technologies, Inc.	Multiple agent therapy for sexual dysfunction
IL139073A0 (en) *	1999-10-21	2001-11-25	Pfizer	Treatment of neuropathy
NZ524572A (en)	2000-09-06	2004-08-27	Tanabe Seiyaku Co	Oral compositions comprising phosphodiesterase inhibitors ( PDE inhibitor )and an acidic substance such as fumaric acid with improved drug efficacy due to decrease solubility in neutral and alkaline regions
GB0025782D0 (en) *	2000-10-20	2000-12-06	Pfizer Ltd	Use of inhibitors
US6548508B2 (en)	2000-10-20	2003-04-15	Pfizer, Inc.	Use of PDE V inhibitors for improved fecundity in mammals
NZ527585A (en)	2001-02-15	2005-04-29	Tanabe Seiyaku Co	Tablets quickly disintegrated in oral cavity
KR100393160B1 (ko) *	2001-06-14	2003-07-31	한국과학기술연구원	신규한 피라졸로피리미딘티온 유도체, 그의 제법 및발기부전 치료제로서의 용도
DE60222931T2 (de)	2001-12-13	2008-07-10	Asubio Pharma Co., Ltd.	Pyrazolopyrimidinonderivate mit pde7-hemmender wirkung
DE10238723A1 (de)	2002-08-23	2004-03-11	Bayer Ag	Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de)	2002-08-23	2004-03-04	Bayer Ag	Alkyl-substituierte Pyrazolpyrimidine
DE10238722A1 (de)	2002-08-23	2004-03-11	Bayer Ag	Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
GB0219961D0 (en)	2002-08-28	2002-10-02	Pfizer Ltd	Oxytocin inhibitors
US7323462B2 (en)	2002-12-10	2008-01-29	Pfizer Inc.	Morpholine dopamine agonists
WO2004054560A1 (en)	2002-12-13	2004-07-01	Warner-Lambert Company Llc	Alpha-2-delta ligand to treat lower urinary tract symptoms
US20050048573A1 (en) *	2003-02-03	2005-03-03	Plexxikon, Inc.	PDE5A crystal structure and uses
DE10320785A1 (de)	2003-05-09	2004-11-25	Bayer Healthcare Ag	6-Arylmethyl-substituierte Pyrazolopyrimidine
US8044060B2 (en)	2003-05-09	2011-10-25	Boehringer Ingelheim International Gmbh	6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
CN100374441C (zh) *	2003-06-06	2008-03-12	天津倍方科技发展有限公司	二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
JP2006219373A (ja) *	2003-06-13	2006-08-24	Daiichi Asubio Pharma Co Ltd	Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
DE10328479A1 (de)	2003-06-25	2005-01-13	Bayer Ag	6-Arylamino-5-cyano-4-pyrimidinone
US20050079548A1 (en) *	2003-07-07	2005-04-14	Plexxikon, Inc.	Ligand development using PDE4B crystal structures
WO2005028480A2 (en) *	2003-09-03	2005-03-31	Neurogen Corporation	5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
US7291640B2 (en)	2003-09-22	2007-11-06	Pfizer Inc.	Substituted triazole derivatives as oxytocin antagonists
DE102004001873A1 (de)	2004-01-14	2005-09-29	Bayer Healthcare Ag	Cyanopyrimidinone
BRPI0506994A (pt)	2004-01-22	2007-07-03	Pfizer	derivados de triazol que inibem a atividade antagonista da vasopressina
US20070093493A1 (en) *	2005-10-12	2007-04-26	Lilly Icos Llc	Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
US7737149B2 (en) *	2006-12-21	2010-06-15	Astrazeneca Ab	N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
JP5498392B2 (ja)	2007-11-30	2014-05-21	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA105362C2 (en)	2008-04-02	2014-05-12	Бьорингер Ингельхайм Интернациональ Гмбх	1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
MX2010014234A (es) *	2008-06-19	2011-03-25	Astrazeneca Ab	Compuestos pirazol 436.
JP5453431B2 (ja)	2008-09-08	2014-03-26	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用
EP2379076B1 (de)	2008-12-23	2014-11-12	The Trustees of Columbia University in the City of New York	Phosphodiesterase-hemmer und ihre verwendungen
PE20120505A1 (es)	2009-03-31	2012-05-09	Boehringer Ingelheim Int	Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
PL390079A1 (pl) *	2009-12-30	2011-07-04	Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna	Sposób otrzymywania wardenafilu i jego izolacji jako soli z kwasem cytrynowym oraz krystaliczna postać tej soli
AP2012006631A0 (en)	2010-08-12	2012-12-31	Boehringer Ingelheim Int	6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
CN102382129B (zh) *	2010-08-19	2014-02-26	山东轩竹医药科技有限公司	螺环取代的磷酸二酯酶抑制剂
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US8809345B2 (en)	2011-02-15	2014-08-19	Boehringer Ingelheim International Gmbh	6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
US9402877B2 (en)	2011-11-04	2016-08-02	Xion Pharmaceuticals Corporation	Methods and compositions for oral administration of melanocortin receptor agonist compounds
ES2623652T3 (es) *	2011-12-28	2017-07-11	Allergan, Inc.	Derivados de 3-fenil-5-ureidoisotiazol-4-carboximida y 3-amino-5-fenilisotiazol como inhibidores de cinasa
ES2704744T3 (es)	2012-06-13	2019-03-19	Incyte Holdings Corp	Compuestos tricíclicos sustituidos como inhibidores de FGFR
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
US20140179712A1 (en)	2012-12-21	2014-06-26	Astrazeneca Ab	Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
EA035095B1 (ru)	2013-04-19	2020-04-27	Инсайт Холдингс Корпорейшн	Бициклические гетероциклы в качестве ингибиторов fgfr
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
MX373169B (es)	2015-02-20	2020-04-24	Incyte Holdings Corp	Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
PL3377495T3 (pl)	2015-11-16	2022-05-16	Topadur Pharma Ag	Pochodne 2-fenylo-3,4-dihydropirolo[2,1-f] [1,2,4]triazynonu jako inhibitory fosfodiesterazy i ich zastosowania
JP7111720B2 (ja)	2016-12-28	2022-08-02	ダート・ニューロサイエンス・エルエルシー	Ｐｄｅ２阻害剤としての置換ピラゾロピリミジノン化合物
KR102670626B1 (ko)	2017-05-22	2024-05-29	토파두르 파마 아게	가용성 구아닐레이트 사이클라제 활성제 및 포스포디에스테라제 억제제의 신규한 이중 작용 방식 및 이의 용도
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CA3120971A1 (en)	2017-11-27	2019-05-31	Dart Neuroscience, Llc	Substituted furanopyrimidine compounds as pde1 inhibitors
MA52493A (fr)	2018-05-04	2021-03-10	Incyte Corp	Sels d'un inhibiteur de fgfr
CR20200590A (es)	2018-05-04	2021-04-26	Incyte Corp	Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
WO2020109354A1 (en)	2018-11-28	2020-06-04	Topadur Pharma Ag	Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
TWI891666B (zh)	2019-10-14	2025-08-01	美商英塞特公司	作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt)	2019-12-04	2022-08-16	Incyte Corp	Derivados de um inibidor de fgfr
EP4069696A1 (de)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclische heterocyclen als fgfr-inhibitoren
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
US11590209B2 (en)	2020-01-21	2023-02-28	Palatin Technologies, Inc.	Use of bremelanotide in patients with controlled hypertension
WO2021245192A1 (en)	2020-06-04	2021-12-09	Topadur Pharma Ag	Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
TW202304459A (zh)	2021-04-12	2023-02-01	美商英塞特公司	包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
WO2022261159A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
EP4352059A1 (de)	2021-06-09	2024-04-17	Incyte Corporation	Tricyclische heterocyclen als fgfr-inhibitoren
CA3228160A1 (en)	2021-09-29	2023-04-06	Topadur Pharma Ag	Topical compositions of 2-phenyl-3,4-dihydropyrrolo[2,l-f] [1,2,4]triazinone derivatives and uses thereof
JP2025506878A (ja)	2022-03-02	2025-03-13	トパデュールファルマアーゲー	局所組成物及びその使用
KR20230129639A (ko)	2022-03-02	2023-09-11	연세대학교 산학협력단	이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태
TW202425999A (zh) *	2022-10-19	2024-07-01	英商卡爾維斯塔製藥有限公司	酶抑制劑

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4871843A (en)	1983-10-18	1989-10-03	Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle	Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
US4663326A (en)	1985-04-04	1987-05-05	Warner-Lambert Company	Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
US4666908A (en)	1985-04-05	1987-05-19	Warner-Lambert Company	5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US5075310A (en)	1988-07-01	1991-12-24	Smith Kline & French Laboratories, Ltd.	Pyrimidone derivatives as bronchodilators
US5250534A (en)	1990-06-20	1993-10-05	Pfizer Inc.	Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) *	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
GB9114760D0 (en) *	1991-07-09	1991-08-28	Pfizer Ltd	Therapeutic agents
GB9119704D0 (en)	1991-09-14	1991-10-30	Pfizer Ltd	Therapeutic agents
FR2681865B1 (fr) *	1991-10-01	1993-11-19	Bel Laboratoire Roger	Nouveaux derives de la benzonaphtyridine-1,8 leur preparation et les compositions qui les contiennent.
GB9121028D0 (en) *	1991-10-03	1991-11-13	Pfizer Ltd	Therapeutic agents
GB9126260D0 (en)	1991-12-11	1992-02-12	Pfizer Ltd	Therapeutic agents
US5294612A (en)	1992-03-30	1994-03-15	Sterling Winthrop Inc.	6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
GB9213623D0 (en) *	1992-06-26	1992-08-12	Pfizer Ltd	Therapeutic agents
US5734053A (en)	1992-06-26	1998-03-31	Pfizer Inc	Purinone antianginal agents
GB9218322D0 (en)	1992-08-28	1992-10-14	Pfizer Ltd	Therapeutic agents
GB9311920D0 (en) *	1993-06-09	1993-07-28	Pfizer Ltd	Therapeutic agents
GB9315017D0 (en) *	1993-07-20	1993-09-01	Glaxo Lab Sa	Chemical compounds
GB9423911D0 (en) *	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
GB9423910D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
JP3713783B2 (ja) *	1995-01-20	2005-11-09	大正製薬株式会社	１Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体
US5656629A (en) *	1995-03-10	1997-08-12	Sanofi Winthrop, Inc.	6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
CZ280697A3 (cs) *	1995-03-10	1998-04-15	Sanofi Pharmaceuticals, Inc.	6 aryl-pyrazolo(3,4-d)pyrimidin-4-ony a kompozice je obsahující, a způsob jejich použití
GB9612514D0 (en) *	1996-06-14	1996-08-14	Pfizer Ltd	Novel process
DE19709877A1 (de) *	1997-03-11	1998-09-17	Bayer Ag	1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
EP0977756A1 (de) *	1997-04-25	2000-02-09	Pfizer Limited	Pyrazolopyrimidinone, die den typ 5 der cyclischen guanosin 3',5'-monophosphat phospodiesterase (cgmp pde5) hemmen, zur behandlung von sexuellen funktionsstörungen
HRP20000712A2 (en) *	1998-04-20	2001-06-30	Pfizer	PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION

1998
- 1998-10-23 GB GBGB9823103.8A patent/GB9823103D0/en not_active Ceased
1999
- 1999-10-15 EP EP99308158A patent/EP0995751B1/de not_active Expired - Lifetime
- 1999-10-15 DE DE69925970T patent/DE69925970T2/de not_active Expired - Fee Related
- 1999-10-15 ES ES99308158T patent/ES2243037T3/es not_active Expired - Lifetime
- 1999-10-15 AT AT99308158T patent/ATE298753T1/de not_active IP Right Cessation
- 1999-10-22 BR BR9905109-5A patent/BR9905109A/pt not_active Application Discontinuation
- 1999-10-22 CA CA002287562A patent/CA2287562A1/en not_active Abandoned
- 1999-10-22 US US09/425,095 patent/US6407114B1/en not_active Expired - Fee Related
- 1999-10-25 JP JP30206499A patent/JP3670908B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP3670908B2 (ja)	2005-07-13
US6407114B1 (en)	2002-06-18
EP0995751A3 (de)	2000-10-18
EP0995751B1 (de)	2005-06-29
GB9823103D0 (en)	1998-12-16
BR9905109A (pt)	2000-09-26
JP2000128884A (ja)	2000-05-09
ES2243037T3 (es)	2005-11-16
EP0995751A2 (de)	2000-04-26
DE69925970T2 (de)	2006-04-27
DE69925970D1 (de)	2005-08-04
CA2287562A1 (en)	2000-04-23

Legal Events

Date	Code	Title	Description
2005-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69925970D1 (de)	2005-08-04	Pyrazolopyrimidinone cGMP PDE5 Inhibitoren zur Behandlung der sexuellen Dysfunktion
DE69911448D1 (de)	2003-10-23	Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen
CA2287552A1 (en)	2000-04-23	Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
BR0004779A (pt)	2001-05-29	Compostos farmaceuticamente ativos
ATE283856T1 (de)	2004-12-15	Zyklische guanosine 3',5'-monophosphate phosphodiesterase inhibitoren
AP2002002455A0 (en)	2002-06-30	5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
ATE298238T1 (de)	2005-07-15	Pyrazolo(4,3-d)pyrimidinon-verbindungen als cgmp pde-inhibitoren
CA2322900A1 (en)	2001-04-11	2-(hetero)aryl-substituted purin-6-ones as phosphodiesterase inhibitors
WO2002064590A3 (en)	2003-02-27	Carboline derivatives
BR0212924A (pt)	2005-01-04	Inibidores de glicogênio sintase quinase-3 (gsk-3) para o tratamento de glaucoma
WO2002064591A3 (en)	2002-12-12	Carboline derivatives
WO2002028865A3 (en)	2003-02-27	Condensed pyridoindole derivatives
WO2002000657A3 (en)	2002-06-13	Condensed pyrazindione derivatives
ATE348101T1 (de)	2007-01-15	Carbolin derivate als hemmstoffe von phospphodiesterase 5 (pde5) zur behandlung kardiovaskulärer erkrankungen und der erektilen dysfunktion
IL149586A0 (en)	2002-11-10	Pyrimidine derivatives as selective inhibitors of cox-2
WO2002079203A8 (en)	2002-11-21	Imidazo-triazine derivatives as pde 5 inhibitors
DE60226970D1 (de)	2008-07-17	Pyrazinoä1',2':1,6ü-pyridoä3,4-bü indole-1,4-dionderivate
AP2002002462A0 (en)	2002-06-30	Pharmaceutically active compounds.
EP1241170A3 (de)	2003-03-12	Pyrazolopyrimidinderivate
ATE296631T1 (de)	2005-06-15	Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation
ECSP003706A (es)	2002-05-23	Compuestos farmaceuticamente activos